Show simple item record

dc.contributor.authorYoung, Megan K
dc.contributor.authorNg, Shu-Kay
dc.contributor.authorNimmo, Graeme R
dc.contributor.authorCripps, Allan W
dc.date.accessioned2019-07-04T12:34:50Z
dc.date.available2019-07-04T12:34:50Z
dc.date.issued2018
dc.identifier.issn1742-5255
dc.identifier.doi10.1080/17425255.2018.1484449
dc.identifier.urihttp://hdl.handle.net/10072/383194
dc.description.abstractBackground: It is unclear whether recommended doses of intramuscular polyvalent immune globulin are optimal for both effectiveness and efficiency of disease prevention when administered post-exposure to measles and rubella. Methods: The peak concentration and decay of disease-specific antibodies after intramuscular dosing of polyvalent immune globulin in adults were modeled using published pharmacokinetic parameters and product disease-specific antibody concentrations. Models simulated dosing according to current Australian guidelines, then adjusted the dose in clinically relevant increments to estimate the optimal dose of disease-specific immunoglobulins for post-exposure prophylaxis of nonimmune individuals against measles and rubella. Optimal dosing assumed a target serum concentration of disease-specific antibodies of the correlate of protection plus a 10% margin of error at an incubation period. Results: Current Australian guidelines appeared to underdose a measles-naïve subpopulation. The optimal dose of measles-specific antibodies was 17.5 IU/kg assuming 75% bioavailability and 25.5 IU/kg assuming 50% bioavailability. Current Australian guidelines recommend 520 IU/kg rubella antibodies for an 80-kg individual. This model suggests that 13 IU/kg is more than sufficient. Conclusions: The recommended dose of intramuscular polyvalent immune globulin should be increased following measles exposure and decreased following rubella exposure for recommended subgroups. These models may be adapted for use internationally.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTD
dc.relation.ispartofpagefrom663
dc.relation.ispartofpageto669
dc.relation.ispartofissue7
dc.relation.ispartofjournalEXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
dc.relation.ispartofvolume14
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchcode3214
dc.titleThe optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorNg, Shu Kay Angus
gro.griffith.authorCripps, Allan W.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record